Edesa Biotech Appoints New CMO, Elects Directors

TL;DR

Edesa Biotech just named a new CMO and added two directors to the board. Big changes coming?

AI Summary

Edesa Biotech, Inc. announced on May 30, 2024, the appointment of Dr. Parimal Sadhu as Chief Medical Officer and the election of Dr. Michael R. Bristow and Dr. Michael J. Ybarra to its Board of Directors. The company also disclosed compensatory arrangements for its officers.

Why It Matters

The appointment of a new Chief Medical Officer and the addition of experienced directors to the board can signal strategic shifts and potential advancements in the company's drug development pipeline.

Risk Assessment

Risk Level: medium — Changes in key leadership and board composition can introduce uncertainty regarding future strategy and execution, impacting the company's risk profile.

Key Players & Entities

• Edesa Biotech, Inc. (company) — Filer
• Dr. Parimal Sadhu (person) — Appointed Chief Medical Officer
• Dr. Michael R. Bristow (person) — Elected to Board of Directors
• Dr. Michael J. Ybarra (person) — Elected to Board of Directors
• Stellar Biotechnologies, Inc. (company) — Former Company Name

FAQ

Filing Documents

• edsa_8k.htm (8-K) — 53KB
• edsa_ex101.htm (EX-10.1) — 9KB
• 0001654954-24-007083.txt ( ) — 184KB
• edsa-20240530.xsd (EX-101.SCH) — 6KB
• edsa-20240530_lab.xml (EX-101.LAB) — 14KB
• edsa-20240530_cal.xml (EX-101.CAL) — 1KB
• edsa-20240530_pre.xml (EX-101.PRE) — 9KB
• edsa-20240530_def.xml (EX-101.DEF) — 2KB
• edsa_8k_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. At the Annual Meeting, 1,517,529 common shares, or approximately 47% of the outstanding common shares entitled to vote, were represented by proxy or in person. The matters voted on by shareholders at the Annual Meeting and the results of such voting are set forth below. Proposal No. 1 – Election of the Company's Directors Based upon the following votes, the shareholders elected Joan Chypyha, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Frank Oakes, Charles Olson and Carlo Sistilli to serve as members of the Company's board of directors until the annual meeting of shareholders to be held in 2025 or until their successors are duly elected and qualified. For Withheld Broker Non-Votes Joan Chypyha 818,559 44,569 654,401 Sean MacDonald 819,376 43,752 654,401 Patrick Marshall 819,174 43,954 654,401 Pardeep Nijhawan, MD 819,448 43,680 654,401 Frank Oakes 790,073 73,055 654,401 Charles Olson, D.Sc. 817,703 45,425 654,401 Carlo Sistilli, CPA, CMA 817,020 46,108 654,401 Proposal No. 2 – Advisory Vote on Executive Compensation The shareholders approved, on an advisory basis, the executive compensation of the named executive officers as disclosed in the proxy statement for the Annual Meeting, by the following vote. For Against Abstain Broker Non-Votes 677,967 122,761 62,400 654,401 Proposal No. 3 – Amendment to 2019 Equity Incentive Compensation Plan The shareholders approved the amendment to the 2019 Plan to increase the number of shares available for issuance under the 2019 Plan by 67,000 shares as disclosed in the proxy statement for the Annual Meeting, by the following vote. For Against Abstain Broker Non-Votes 660,015 151,395 51,718 654,401 Proposal No. 4 – Appointment of MNP LLP as the Company's Auditors and Independent Registered Public Accounting Firm for the Ensuing Year Based upon the following votes,

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1* Amendment No. 3 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Management contract or compensatory plan or arrangement. 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Edesa Biotech, Inc. Date: May 30, 2024 By: /s/ Stephen Lemieux Name: Stephen Lemieux Title: Chief Financial Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR